Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Replimune Group, Inc. (REPL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 4 Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 18,600 shares @ $20.01, valued at $372.2k
Exercised 13,600 options to buy @ $3.3, valued at $44.9k
Exercised 5,000 options to buy @ $15.5, valued at $77.5k
08/15/2023 4 Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 1,400 shares @ $20, valued at $28k
Exercised 1,400 options to buy @ $3.3, valued at $4.6k
08/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
08/03/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update",
"Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB099280 in Patients with Cutaneous Squamous Cell Carcinoma"
07/26/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/26/2023 ARS Form ARS - Annual Report to Security Holders:
07/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/20/2023 8-K Quarterly results
07/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/10/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 4 Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 12,043 shares @ $24.1, valued at $290.2k
Sold 817 shares @ $23.45, valued at $19.2k
06/15/2023 4 Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 5,145 shares @ $24.11, valued at $124k
Sold 553 shares @ $23.44, valued at $13k
05/18/2023 3 Schwendenman Andrew (Chief Accounting Officer) has filed a Form 3 on Replimune Group, Inc.
05/18/2023 4 Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 15,575 shares @ $18.05, valued at $281.1k
05/18/2023 4 Coffin Robert (President & Chief R&D Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 7,861 shares @ $18.05, valued at $141.9k
05/18/2023 4 Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 12,207 shares @ $18.05, valued at $220.3k
05/18/2023 4 Love Colin (COO) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 10,775 shares @ $18.05, valued at $194.5k
05/18/2023 4 Franchi Jean M. (CFO) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 11,351 shares @ $18.05, valued at $204.9k
05/18/2023 4 Xynos Konstantinos (Chief Medical Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 771 shares @ $18.05, valued at $13.9k
05/18/2023 4 Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 5,966 shares @ $18.05, valued at $107.7k
05/18/2023 4 Astley-Sparke Philip (CEO) has filed a Form 4 on Replimune Group, Inc.
Txns: Sold 17,902 shares @ $18.05, valued at $323.1k
05/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/18/2023 10-K Annual Report for the period ended March 31, 2023
05/18/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update"
04/04/2023 4 Slootweg Hugo Alexander (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
04/04/2023 4 Pucci Paolo (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
04/04/2023 4 Dhingra Kapil (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
04/04/2023 4 SLATTERY JOSEPH P (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
04/04/2023 4 Levitsky Hyam (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
04/04/2023 4 Weinand Dieter (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 37,800 options to buy @ $17.66, valued at $667.5k
04/04/2023 4 Oliger Christy J. (Director) has filed a Form 4 on Replimune Group, Inc.
Txns: Granted 25,200 options to buy @ $17.66, valued at $445k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy